Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on M&C Saatchi as tariff fallout hits guidance

(Sharecast News) - Analysts at Berenberg lowered their target price on advertising agency M&C Saatchi from 240p to 200p on Thursday following the group's interim results, released earlier in the morning. Berenberg stated that due to client caution in Q2 following Donald Trump's "liberation day" tariff announcement, M&C had downgraded its like-for-like revenue guidance to a mid-single digit decline.

Berenberg noted that due to swift action taken on costs, M&C now expects full-year underlying earnings to be in line with last year, which resulted in an 8% downgrade to its underlying earnings forecast.

However, the German bank also said that with the shares having derated by 13% over the last three months, it believes that the market was already factoring in some of this weakness.

Berenberg said: "We continue to like M&C due to the actions the new management team have taken to improve efficiencies across the group, the focus on improving the mix to higher-growth, higher-margin divisions, and the capital-allocation optionality provided by its improving free cash-flow profile," said Berenberg.

"For its outlook statement, the company notes that it now expects FY25 LFL revenue will be down mid-single digits and is targeting FY25 EBIT to be in line with last year. We now forecast LFL revenue growth of -5% (versus our prior forecast of 2%), and our net revenue forecast falls 8% to £216m."

Berenberg added that M&C currently trades on a full-year price-to-earnings ratio of 9.4x, and a free cash flow yield of 5.5% on its new numbers.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.